Metabolomic Profiling as a Possible New Method For Predicting Cardiovascular Toxicity of Chemotherapy: a Pilot...

Area of Science:

• Cardiovascular Medicine
• Oncology
• Metabolomics

Background:

• Antitumor therapy (ATT) poses a risk of cardiovascular toxicity in oncohematological patients.
• Early detection of cardiovascular risk factors is crucial for patient management.

Purpose of the Study:

• To identify metabolomic profiles and vascular parameters associated with cardiovascular toxicity risk from ATT.
• To develop a predictive model for cardiovascular complications in lymphoma and multiple myeloma patients.

Main Methods:

• Included 59 oncohematological patients (34 lymphomas, 25 multiple myeloma).
• Assessed vascular function (photoplethysmography, echocardiography) and metabolomic profiles (98 metabolites) before and after ATT.
• Utilized logistic regression for predictive modeling.

Main Results:

• Patients exhibited endothelial dysfunction and increased vascular stiffness pre-ATT, worsening post-treatment.
• Identified specific amino acids, acylcarnitines, choline, and tryptophan metabolites linked to cardiovascular toxicity risk.
• Developed a logistic regression model with high prognostic power (AUC = 0.84) for predicting ATT-induced cardiovascular toxicity.

Conclusions:

• Key metabolites and vascular parameters can predict cardiovascular complications risk before ATT initiation.
• Elevated amino acids, acylcarnitines, and choline metabolites are potential risk factors for cardiovascular issues.
• An integrated approach of metabolomic profiling and vascular assessment enables personalized cardioprotection and monitoring during ATT.